Abstract 122P
Background
Cribriform (cbf) morphology has been shown in carcinomas from various organs, including prostate and breast, to be associated with worse patient outcomes and unique molecular features. We sought to examine the multimodal data from the landmark Cancer Genome Atlas (TCGA) study to clarify molecular and prognostic factors associated with cbf morphology in colorectal adenocarcinomas.
Methods
We retrospectively analyzed the available TCGA CRC cohort (n=594). Clinicopathological, digital slides, and molecular data were extracted. Cases with insufficient clinical data, no diagnostic slides, or poor slide quality were excluded. TCGA coded data, pathology reports, and digital diagnostic slides were reassessed by one gastrointestinal pathologist and a resident. Cbf morphology was graded using five categories based on prostate cribriform studies: (0) no-cribriform, (1) loose cribriform, (2) small cribriforming glands, (3) diffuse large cribriform, and (4) intraductal carcinoma of the prostate-like. Cases were grouped into cbf 'low' (0-1) and cbf 'high' (2-4) groups, which were correlated with clinicopathological, histological and molecular features. Immune infiltration was characterized by cell type fraction. An adjusted α = 0.05 for statistical significance was used for all tests.
Results
573 CRC cases were included. Cbf 'high' CRCs (159/573) were associated with more left-sided tumors (p=0.049), metastatic diseases (p=0.0001), less MSI-H (p=0.003), and different aneuploidy and fraction genome altered (p=0.003-0.008). Cbf 'high' vs 'low' tumors did not show a significant difference in grading distribution. T and N staging were not associated with cbf morphology. By cell fraction, cbf ‘high’ CRCs showed an immune infiltrate with increased regulatory T cells (p<0.0001) but decreased memory B cells (p=0.046), M2 macrophages (p<0.0001), neutrophils (p=0.018), resting dendritic cells (p=0.046), compared with cbf ‘low’ CRCs. Cbf 'high' tumor morphology was associated with worse overall survival outcomes by log-rank testing (p=0.037).
Conclusions
Cribriform morphology in colorectal adenocarcinoma TCGA cases was associated with poorer outcomes and distinct transcriptomic immune profiling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Q-H. Trinh.
Funding
Fonds de recherche Santé Québec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract